Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer
The Prostate · 2025-09 · 85 (12) · 1151-1154
DOI: 10.1002/pros.24923 ↗Abstract
ABSTRACT Background While their indications overlap, no clinical trials have compared abiraterone and enzalutamide for overall survival (OS) in mCRPC. Methods A large, country‐wide health insurance database (2013‐2023) was assessed for the OS comparison between abiraterone and enzalutamide. Results Overall, 3497 patients were identified with first‐ ( n = 2215) or second‐line ( n = 1282) abiraterone or enzalutamide treatment (only 66 received both drugs sequentially). Enzalutamide‐treated patients had longer OS both in the first‐ (HR:0.84; 95%CI:0.74‐0.96; p = 0.008) and the second‐line setting (HR:0.88; 95%CI:0.78‐0.99; p = 0.043), respectively. Conclusions This health insurance‐registry‐based study suggests that, in the real‐world mCRPC setting, enzalutamide is superior to abiraterone in terms of OS.
EUVIMED